Tseng-Tien Huang1, Melissa M Hudson2, Dennis C Stokes3, Matthew J Krasin4, Sheri L Spunt2, Kirsten K Ness5. 1. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN. Electronic address: tseng.huang@stjude.org. 2. Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN. 3. Department of Pediatric Pulmonary Medicine, St. Jude Children's Research Hospital, Memphis, TN. 4. Department of Radiological Sciences, St. Jude Children's Research Hospital, Memphis, TN. 5. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN.
Abstract
BACKGROUND: The purpose of this article is to summarize the literature that documents the long-term impact of cancer treatment modalities on pulmonary function among survivors of cancer and to identify potential areas for further research. METHODS: Systematic reviews of clinical trials, observational studies, case series, and review articles were conducted. Articles were limited to the studies that discussed pulmonary toxicity or late effects among pediatric cancer survivors and to follow-up investigations that were conducted a minimum of 2 years after completion of cancer-related treatment or 1 year after hematopoietic stem cell transplant. RESULTS: Sixty publications (51 clinical studies/reports and nine reviews) published from January 1970 to June 2010 in PubMed met the inclusion criteria. Data showed an association between radiotherapy, alkylating agents, bleomycin, hematopoietic stem cell transplant, and thoracic surgery and pulmonary toxicity, as well as possible interactions among these modalities. CONCLUSIONS: Pulmonary toxicity is a common long-term complication of exposure to certain anticancer therapies in childhood and can vary from subclinical to life threatening. Pulmonary function and associated loss of optimal exercise capacity may have adverse effects on long-term quality of life in survivors. Lung function diminishes as a function of normal aging, and the effects of early lung injury from cancer therapy may compound these changes. The information presented in this review is designed to provide a stimulus to promote both observational and interventional research that expands our knowledge and aids in the design of interventions to prevent or ameliorate pulmonary late effects among survivors of childhood cancer.
BACKGROUND: The purpose of this article is to summarize the literature that documents the long-term impact of cancer treatment modalities on pulmonary function among survivors of cancer and to identify potential areas for further research. METHODS: Systematic reviews of clinical trials, observational studies, case series, and review articles were conducted. Articles were limited to the studies that discussed pulmonary toxicity or late effects among pediatric cancer survivors and to follow-up investigations that were conducted a minimum of 2 years after completion of cancer-related treatment or 1 year after hematopoietic stem cell transplant. RESULTS: Sixty publications (51 clinical studies/reports and nine reviews) published from January 1970 to June 2010 in PubMed met the inclusion criteria. Data showed an association between radiotherapy, alkylating agents, bleomycin, hematopoietic stem cell transplant, and thoracic surgery and pulmonary toxicity, as well as possible interactions among these modalities. CONCLUSIONS:Pulmonary toxicity is a common long-term complication of exposure to certain anticancer therapies in childhood and can vary from subclinical to life threatening. Pulmonary function and associated loss of optimal exercise capacity may have adverse effects on long-term quality of life in survivors. Lung function diminishes as a function of normal aging, and the effects of early lung injury from cancer therapy may compound these changes. The information presented in this review is designed to provide a stimulus to promote both observational and interventional research that expands our knowledge and aids in the design of interventions to prevent or ameliorate pulmonary late effects among survivors of childhood cancer.
Authors: Hiroto Inaba; Jie Yang; Jianmin Pan; Dennis C Stokes; Matthew J Krasin; Ashok Srinivasan; Christine M Hartford; Ching-Hon Pui; Wing Leung Journal: Cancer Date: 2010-04-15 Impact factor: 6.860
Authors: Melissa M Hudson; Daniel A Mulrooney; Daniel C Bowers; Charles A Sklar; Daniel M Green; Sarah S Donaldson; Kevin C Oeffinger; Joseph P Neglia; Anna T Meadows; Leslie L Robison Journal: J Clin Oncol Date: 2009-03-16 Impact factor: 44.544
Authors: Jeremy R Grushka; Jon Ryckman; Claudia Mueller; Anthony de Buys Roessingh; J Mark Walton; Dickens St Vil; Jean-Martin Laberge; Chantal Bernard; Van-Hung Nguyen; Pramod S Puligandla Journal: J Pediatr Surg Date: 2009-05 Impact factor: 2.545
Authors: Gregory T Armstrong; Qi Liu; Yutaka Yasui; Joseph P Neglia; Wendy Leisenring; Leslie L Robison; Ann C Mertens Journal: J Clin Oncol Date: 2009-03-30 Impact factor: 44.544
Authors: Andriani G Charpidou; Ioannis Gkiozos; Sotirios Tsimpoukis; Despoina Apostolaki; Kalliopi D Dilana; Eleni M Karapanagiotou; Kostas N Syrigos Journal: Anticancer Res Date: 2009-02 Impact factor: 2.480
Authors: Tseng Tien Huang; Yan Chen; Andrew C Dietz; Yutaka Yasui; Sarah S Donaldson; Dennis C Stokes; Marilyn Stovall; Wendy M Leisenring; Charles A Sklar; Lisa R Diller; Ann C Mertens; Gregory T Armstrong; Daniel M Green; Leslie L Robison; Kirsten K Ness Journal: Pediatr Blood Cancer Date: 2013-10-11 Impact factor: 3.167
Authors: Gregory T Armstrong; Vijaya M Joshi; Liang Zhu; Deokumar Srivastava; Nan Zhang; Kirsten K Ness; Dennis C Stokes; Matthew T Krasin; James A Fowler; Leslie L Robison; Melissa M Hudson; Daniel M Green Journal: J Clin Oncol Date: 2013-01-07 Impact factor: 44.544
Authors: Tyler A Beach; Carl J Johnston; Angela M Groves; Jacqueline P Williams; Jacob N Finkelstein Journal: Exp Lung Res Date: 2017-05-23 Impact factor: 2.459
Authors: Andrew B Smitherman; Danielle Mohabir; Tania M Wilkins; Julie Blatt; Hazel B Nichols; Stacie B Dusetzina Journal: J Pediatr Date: 2018-02-12 Impact factor: 4.406
Authors: S Cristina Oancea; James G Gurney; Kirsten K Ness; Rohit P Ojha; Vida L Tyc; James L Klosky; DeoKumar Srivastava; Dennis C Stokes; Leslie L Robison; Melissa M Hudson; Daniel M Green Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-06-17 Impact factor: 4.254
Authors: Yin Ting Cheung; Michelle N Edelmann; Daniel A Mulrooney; Daniel M Green; Wassim Chemaitilly; Neena John; Leslie L Robison; Melissa M Hudson; Kevin R Krull Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-06-26 Impact factor: 4.254
Authors: Andrew C Dietz; Yan Chen; Yutaka Yasui; Kirsten K Ness; James S Hagood; Eric J Chow; Marilyn Stovall; Joseph P Neglia; Kevin C Oeffinger; Ann C Mertens; Leslie L Robison; Gregory T Armstrong; Daniel A Mulrooney Journal: Cancer Date: 2016-08-09 Impact factor: 6.860